Literature DB >> 10751236

Risk factors for central nervous system involvement in systemic lupus erythematosus.

F B Karassa1, J P Ioannidis, G Touloumi, K A Boki, H M Moutsopoulos.   

Abstract

We investigated risk factors for central nervous system (CNS) involvement in systemic lupus erythematosus (SLE), in 32 such patients individually matched 1 : 3 to 96 control SLE patients without CNS events. Univariate analysis showed that CNS involvement was significantly associated with the antiphospholipid syndrome (APS) as well as its features: arterial thrombosis, recurrent fetal loss, livedo reticularis and IgG anticardiolipin (aCL) antibodies in high titres. Other potential associations included cutaneous vasculitic lesions, thrombocytopenia, positive ANA, anti-SS-B/La and low serum levels of C(3) and C(4) complement components, while articular manifestations and discoid rash were significantly less common in patients with neuropsychiatric (NP) disease. In multivariate modeling, CNS involvement was strongly associated with cutaneous vasculitic lesions OR 33, 95% CI 1.5-720) and arterial thromboses (OR 13, 95%CI 0.82-220), and negatively related to the presence of articular manifestations (OR 0.015, 95%CI 0.00-0.17) and discoid rash (OR 0.004, 95%CI 0.00-0.35). Associations with APS-related arterial thromboses and vasculitis point to the importance of arterial vascular pathophysiology in the pathogenesis of NP disease in SLE. Patients with articular manifestations and discoid rash are at very low risk of NP events. Patients with an adverse SLE disease profile may require closer observation and may be the target group for studying pre-emptive interventions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751236     DOI: 10.1093/qjmed/93.3.169

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  24 in total

1.  Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center.

Authors:  Melissa Padovan; Gabriella Castellino; Alessandra Bortoluzzi; Luisa Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

2.  Deep brain reversible encephalopathy: association with secondary antiphospholipid antibody syndrome.

Authors:  T Parikh; K Shifteh; M L Lipton; J A Bello; A L Brook
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

3.  Neurological Manifestations in Systemic Lupus Erythematosus: A Single Centre Study from North East India.

Authors:  Sanjeeb Kakati; Bhupen Barman; Sobur U Ahmed; Masaraf Hussain
Journal:  J Clin Diagn Res       Date:  2017-01-01

Review 4.  Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Authors:  Aaron M Milstone; Kevin Meyers; Josephine Elia
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

Review 5.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

6.  Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort.

Authors:  Yesenia Santiago-Casas; Luis M Vilá; Gerald McGwin; Ryan S Cantor; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Robert P Kimberly; Graciela S Alarcón; Elizabeth E Brown
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 7.  Neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  David Hermosillo-Romo; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

8.  TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.

Authors:  Jing Wen; Jessica Doerner; Karen Weidenheim; Yumin Xia; Ariel Stock; Jennifer S Michaelson; Kuti Baruch; Aleksandra Deczkowska; Maria Gulinello; Michal Schwartz; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2015-04-22       Impact factor: 7.094

9.  Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus.

Authors:  Ahmed M Abdel-Nasser; Rasha M Ghaleb; Jehan A Mahmoud; Wafaa Khairy; Refaat M Mahmoud
Journal:  Clin Rheumatol       Date:  2008-05-15       Impact factor: 2.980

10.  Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.

Authors:  E M Cohen; K D'Silva; D Kreps; M B Son; K H Costenbader
Journal:  Lupus       Date:  2018-02-16       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.